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Abstract 
Aims 
Reported associations between liver enzymes and mortality may not hold true in type 2 diabetes, 
owing to a high prevalence of non-alcoholic fatty liver disease, which has been linked to 
cardiovascular disease and mortality in its own right. Our study aimed to determine whether 
alanine aminotransferase (ALT) or γ-glutamyl transferase (GGT) levels predict mortality in type 
2 diabetes, and to examine possible mechanisms.  
Methods 
Data from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study were 
analysed to examine the relationship between liver enzymes and all-cause and cause-specific 
mortality over 5 years. 
Results 
Over 5 years, 679 (6.9%) individuals died. After adjustment, for every standard deviation 
increase in ALT (13.2U/L), the HR for death on study was 0.85 (95% CI 0.78-0.93), p<0.001. 
Conversely, GGT >70 U/L, compared with GGT ≤70 U/L, had HR 1.82 (1.48−2.24), p<0.001. 
For cause-specific mortality, lower ALT was associated with a higher risk of cardiovascular 
death only, whereas GGT >70 U/L was associated with higher risks of death due to 
cardiovascular disease, cancer and non-cancer/non-cardiovascular causes. The relationship for 
ALT persisted after adjustment for indirect measures of frailty but was attenuated by elevated 
hsCRP. 
Conclusions 
As in the general population, ALT has a negative, and GGT a positive, correlation with mortality 
in type 2 diabetes when ALT is less than two times the upper limit of normal. The relationship 
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for ALT appears specific for death due to cardiovascular disease. Links of low ALT with frailty, 
as a potential mechanism for relationships seen, were neither supported nor conclusively refuted 
by our analysis and other factors are also likely to be important in those with type 2 diabetes. 
Keywords: Mortality, alanine aminotransferase, γ-glutamyl transferase, non-alcoholic fatty liver 
disease, diabetes mellitus 
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Abbreviations 
ALT alanine aminotransferase 
BMI body mass index 
CI confidence interval 
CV coefficient of variation 
eGFR estimated glomerular filtration rate 
ELISA enzyme-linked immunosorbent assay 
GGT γ-glutamyl transferase 
HDL-c high-density lipoprotein cholesterol 
HOMA IR homeostatic model of insulin resistance 
HR hazard ratio 
hsCRP highly sensitive C reactive protein 
IQR interquartile range 
LDL-c low-density lipoprotein cholesterol 
NAFLD non-alcoholic fatty liver disease 
SD standard deviation 
sICAM soluble intercellular cell adhesion molecule 
sVCAM soluble vascular cell adhesion molecule 
WHR waist-hip ratio 
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1. Introduction 
The enzymes alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT) are found within 
many tissues. Blood elevations of ALT and GGT are widely used in clinical practice as markers 
of hepatic dysfunction [1]. GGT, found in hepatocytes and biliary epithelial cells, is a sensitive 
marker of hepatobiliary disease, while blood ALT levels increase when the hepatocyte membrane 
is damaged, as an indicator of hepatocellular injury. Both ALT and GGT are recognised as 
surrogate markers of the metabolic syndrome, fatty liver and cardiovascular disease risk, while 
GGT is also a marker of oxidative stress and systemic inflammation [1-4]. Several recent 
publications report an inverse association between ALT and mortality [5, 6]. While this would 
seem counterintuitive if lower ALT is to be considered a marker of liver health, this observation 
has been repeatedly noted in different populations, including in the elderly, the middle-aged and 
those with HIV infection [5-9]. Intriguingly, the relationship is opposite to that for GGT, which 
has a positive association with mortality [4, 9-11]. 
While the mechanisms behind the positive association between GGT and mortality can easily be 
discerned through the known correlations of GGT with liver disease, oxidative stress, 
inflammation and comorbidities [1, 12], those explaining the inverse relationship between ALT 
and mortality are elusive. Possible links between low ALT and sarcopenia, biological frailty and 
chronological age have been postulated [6, 7]. 
This study aimed to determine whether the relationships between blood levels of ALT and GGT 
and mortality observed in the general population were similar in a community dwelling cohort 
with type 2 diabetes. We surmised that such relationships may not exist in type 2 diabetes as it is 
a condition associated with higher ALT and GGT, largely owing to the presence of non-alcoholic 
fatty liver disease (NAFLD), which is also associated with increased cardiovascular disease and 
mortality [13-15]. A secondary aim was to explore potential mechanisms behind any 
relationships found between ALT and GGT and mortality. 
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2. Patients and methods 
The study was a subsidiary analysis of the FIELD study—a double-blind, placebo-controlled trial 
done in 63 centres in Australia, New Zealand, and Finland [16]. In brief, 9795 participants aged 
50–75 years with type 2 diabetes according to WHO criteria [17] were randomly allocated 
between 1998 and 2000 to once-daily micronized fenofibrate or placebo. Participants had an 
initial total-cholesterol concentration 3.0–6.5 mmol/L, plus either total-cholesterol/HDL-c ratio ≥ 
4.0 or plasma triglyceride concentration 1.0–5.0 mmol/L, and were not on lipid-modifying 
therapy at study entry. Exclusion criteria included: blood creatinine >130 μmol/L, history of 
chronic liver disease, as determined by patient or doctor report, a cardiovascular event within 3 
months of recruitment, ALT > two times the upper limit of normal (> 100 U/L) and a recent 
history of alcohol abuse, as defined by the medical history or at the discretion of the 
investigators. All deaths were adjudicated by an outcomes assessment committee. Total mortality 
and cause-specific mortality were predefined secondary outcomes [16]. 
2.1 Baseline characteristics 
A full clinical assessment was performed at baseline. A history of cardiovascular disease was 
defined as any self-reported history of myocardial infarction, angina, percutaneous transluminal 
coronary angioplasty, coronary artery bypass grafting, stroke, claudication, peripheral vascular 
disease, or peripheral revascularisation. Dyslipidaemia was defined as low HDL-c (<1.03 
mmol/L in men, <1.29 mmol/L in women) and high triglyceride concentration (>1.70 mmol/L). 
Nephropathy was defined as the presence of albuminuria [16]. Alcohol consumption was 
classified as none, infrequent (special occasion to once/week) or regular (≥ 2 times/week); data 
were lacking for grams taken per week. Grade of current exercise capacity using routine daily 
activities (very light, light, moderate, heavy and very heavy; see eTable 1 for more detail), in 
addition to the highest level of education obtained (primary school, some high school, completed 
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high school, some university, completed university) and employment status (full-time, part-time 
and not working) were recorded on all participants at baseline [16]. 
A subset of individuals (n=1956) were randomly allocated to a quality-of-life and economic 
evaluation substudy. As part of this, they were asked to complete the SF-36 questionnaire at 
baseline as a comprehensive and extensively validated, generic, quality-of-life assessment [18]. 
2.2 Laboratory parameters 
During the study, all samples were analysed at one of two laboratories: SA Pathology, Adelaide, 
Australia, or the laboratory of the National Public Health Institute, Helsinki, Finland. Both 
laboratories participated in national quality assurance schemes. ALT and GGT were measured 16 
weeks and ALT again 6 weeks before randomisation. The average of the two ALT measurements 
was used for analysis. All specimens were stored immediately at -20°C and shipped within 7 
days for processing. ALT and GGT assays used standard colorimetric techniques consistent with 
the guidelines of the International Foundation of Clinical Chemistry (IFCC) [19, 20]. Vascular 
cell adhesion molecules were analysed in the laboratory of AJJ and ASJ in the University of 
Melbourne, Department of Medicine using ELISAs (R&D Systems, Minneapolis, MN, USA). 
The intra-assay and inter-assay CVs for sVCAM, sICAM and sE-selectin were 2.07% and 9.37%, 
2.71% and 7.77% and 4.15% and 10.98%, respectively. 
2.3 Statistical analysis  
Analyses were by intention-to-treat using SPSS v22 and ACCORD v2.0.5, confirmed on SAS 
v9.3. Owing to the non-normal distributions of ALT and GGT, their relationship with baseline 
characteristics was determined using Spearman’s correlation for continuous variables and the 
Wilcoxon rank–sum or Kruskal–Wallis test for categorical variables. To assess the relationship 
between baseline ALT and GGT and total mortality, Cox proportional-hazards regression was 
used to compute HRs and 95% CIs. Examined by deciles, the data were consistent with a linear 
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relationship between ALT and cardiovascular events (Fig. 1A and 1B), and so continuous ALT 
(per one SD) was used in predictive models. With similar techniques, GGT had a non-linear 
relationship with time to all-cause mortality (Fig. 1C and 1D), and so analysis was conducted 
using the top decile (GGT > 70 U/L) versus the rest of the cohort. All models were adjusted for 
assignment to fenofibrate, despite fenofibrate use having no association with mortality [16], and 
the following pre-specified baseline variables: age, sex, diabetes duration, hypertension, 
dyslipidaemia, nephropathy, cardiovascular disease, current-smoker status, WHR, HbA1c, and 
LDL-c. Models were tested for appropriateness using co-linearity diagnostics and Harrell Lee 
statistical testing. With identical variables, cause-specific mortality, defined as death due to total 
cardiovascular events, cancer and non-cancer/non-cardiovascular causes, was examined using 
competing risks analysis (Fine and Gray method [21]). 
For all-cause mortality, in post hoc analysis, the multivariable model was further individually 
adjusted for laboratory used, alcohol consumption pattern, level of education, hsCRP, continuous 
HDL-c and triglycerides (to replace dyslipidaemia), body-mass index (BMI, to replace WHR), 
systolic and diastolic blood pressure (to replace the binary variable of hypertension), past and 
present smoking (to replace current smoking), or C-peptide, fasting glucose (to replace HbA1c), 
and diabetes treatment category (diet, oral antidiabetic therapy or insulin±oral therapy), and also 
ALT or GGT, as appropriate. Penalised Cox modelling, with an estimate of treatment effect, was 
then used to adjust for statin therapy use on study [22]. To explore whether ALT might be acting 
as a marker of systemic frailty, the model was individually adjusted for grade of current exercise 
capacity, employment status, eGFR, resting heart rate, and also weight loss over the first 12 
months after exclusion of events in the first 12 months of study in a landmark analysis [23]. 
Analysis was also done after excluding events at one and two years after randomisation. 
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In exploratory analysis, interactions among all predefined baseline variables, in addition to 
variables used for further adjustment, were tested to identify any differential effect of ALT or 
GGT between various categories, with p<0.05 considered significant. If positive interactions 
were found, appropriate sub-analysis was performed, after inspection of data graphically by 
scatter-dot, and also by decile analysis in the case of a continuous variable.  
To further explore the associations between ALT and GGT and surrogate measures of frailty, 
scores out of 100 for each of the eight domains (physical functioning, role limitations due to 
physical health, role limitations due to emotional problems, energy/fatigue, emotional wellbeing, 
social functioning, pain and general health) from the SF-36 were calculated using standard 
techniques in those with available data [24-26]. In this way, a higher score was consistent with 
higher physical and/or emotional function. Given an apparent non-linear relationship between 
domain scores and ALT and GGT, and also a score limit of 100, the cohort was divided into four 
groups by each of the eight domain scores using cut-off values of 0–25, 26–50, 51–75 and 76–
100. The median (interquartile range (IQR)) ALT and GGT was obtained for each of the four 
groups in each domain of the SF-36 and statistical differences were determined using Kruskal-
Wallis test. The primary model was not adjusted for SF-36 scores given that these data were only 
available in 16% of the total cohort. 
2.4   Ethics 
All participants provided written informed consent. The study protocol was approved by local 
and national ethics committees and was undertaken in accordance with the Declaration of 
Helsinki and Good Clinical Practice guidelines. The original trial was registered with the 
International Standard Randomised Controlled Trial Number (ISRCTN) 64783481. 
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3. Results 
3.1 Basic demographics 
The average age of the cohort was 62±7 years. Median (IQR) diabetes duration was 5 (2–10) 
years, HbA1c was 52 (43-62) mmol/mol (6.9 (6.1–7.8) %), and BMI was 29.8 (26.8–33.5) kg/m2. 
At baseline, 2608 (27%) were treated with diet, 5841 (59%) oral anti-diabetic therapy only, and 
1346 (14%) insulin ± oral therapy. 
There were 679 (6.9%) deaths during the study: 316 (3.2%) due to cancer, 267 (2.7%) 
cardiovascular disease and 96 (1.0%) related to non-cancer/non-cardiovascular causes (see 
eTable 2 for more detail). Table 1 details the basic characteristics of those who died compared 
with those who did not. As previously described, 9 (4 in the fenofibrate group) withdrew consent 
and 22 (12 in the fenofibrate group) were lost to follow up [16].  
3.2 ALT, GGT and their clinical and biochemical associations 
The median baseline ALT was 24 (IQR 18–33) U/L and GGT 29 (IQR 21–44) U/L. The 
univariate relationships between ALT and GGT and baseline variables are detailed in Tables 2a 
and 2b and eTable 3. 
3.3 ALT and all-cause mortality 
In a Cox model, per one SD (13.2 U/L) increase in ALT, there was a 19% lower risk for death 
(95% CI 12-26%), p< 0.001. This remained significant after adjustment for assignment to 
fenofibrate, age, sex, diabetes duration, current smoker status, hypertension, dyslipidaemia, 
nephropathy, prior cardiovascular disease, WHR, LDL-c and HbA1c, with a 15% (95% CI 7-
22%) lower risk of death on study, p< 0.001. Substituting continuous HDL-c and triglycerides for 
dyslipidaemia, BMI for WHR, past and present smokers for current smokers, or systolic and 
diastolic blood pressure for hypertension into the primary model had no significant effect on 
relationships seen. When ranked by WALD score, obtained from the adjusted model, ALT was 
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listed 6th, behind age, current smoker status, history of cardiovascular disease, nephropathy and 
HbA1c. 
3.4 GGT and all-cause mortality 
Using Cox-modelling, those with a GGT > 70U/L, when compared to those with GGT ≤ 70 U/L, 
had a HR for death of 1.88 (95% CI 1.53-2.30), p< 0.001. After adjustment for assignment to 
fenofibrate, age, gender, diabetes duration, current smoker status, hypertension, dyslipidaemia, 
nephropathy, history of cardiovascular disease, WHR, LDL-c and HbA1c, this remained 
significant, with a HR for death on study of 1.82 (95% CI 1.48-2.24), p< 0.001. Substituting 
continuous HDL-c and triglycerides for dyslipidaemia, BMI for WHR, past and present smokers 
for current smokers, or systolic and diastolic blood pressure for hypertension into the primary 
model had no significant effect on relationships seen. When variables were ranked by WALD 
score, obtained from the adjusted model, GGT > 70U/L was listed fourth, behind age, current 
smoker status and prior CVD. 
3.5 ALT and GGT and cause-specific mortality 
The HRs for death due to cancer, cardiovascular or non-cancer/non-cardiovascular causes were 
calculated in univariable and multivariable models and are listed in Table 3. To illustrate the 
qualitative nature of the relationships for each cause of death, the data are displayed graphically 
in Fig. 2 using ALT and GGT deciles. 
3.6 Exploring mechanisms for the relationships between ALT and GGT and total 
mortality 
Minimal effect was observed for relationships between ALT and GGT with total mortality when 
multivariable models were further individually adjusted for additional pre-specified variables to 
examine for effects of frailty, co-morbidity, insulin resistance, diabetes treatment, statin 
treatment, alcohol consumption and country of recruitment. Adjustment for hsCRP had no 
significant effect on relationships seen, although adjustment for the circulating soluble forms of 
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vascular inflammation markers, sICAM, sVCAM and sE-Selectin, strengthened associations for 
ALT and weakened associations for GGT (eTable 4 and eTable 5). Of note, grade of current 
exercise capacity had a significant (p<0.001), inverse, stepwise relationship with mortality in its 
own right (data not shown) and was also positively associated with ALT on univariate analysis 
(eTable 3). In addition, relationships persisted, and remained similar in strength, for both ALT 
and GGT when events in the first 1 or 2 years were excluded (eTable 4 and eTable 5). 
When ALT and GGT were adjusted for each other within primary models, relationships with 
mortality were strengthened. When ALT was adjusted for GGT as a linear variable, a 23% (95% 
CI 15–30%) lower risk per one SD increase in ALT was observed, p< 0.001. Similarly, if 
individuals with GGT > 70 U/L were excluded, there was a 26% (95% CI 17–35%) lower risk of 
death per one SD increase in ALT, p< 0.001. For those with GGT > 70 U/L, after adjustment for 
ALT as a continuous variable, the HR for death when compared to those with GGT ≤ 70 IU/L 
was higher, at 2.26 (95% CI 1.82–2.81), p< 0.001. 
There was a statistically significant interaction noted for hsCRP, as a continuous variable and for 
a value > 6.0 mg/L, in the relationship between ALT and total mortality. There was also a 
significant interaction for education level obtained individually and primary school education 
versus the rest of the cohort. Statistically significant interactions were noted between GGT and 
hypertension, diabetes treatment type, hsCRP (as a continuous variable and when > 6.0 mg/L) 
and alcohol consumption pattern. Relevant sub-analyses of the cohort divided by these variables 
is listed in Table 4. 
3.7 Relationships between ALT and GGT and the SF-36 
Data for the 1614 randomly selected participants who had a complete data set for the SF-36 at 
baseline were used in a sub-analysis to look at relationships between ALT and GGT and the 8 
separate domains of the SF-36 (eTable 6). The average age of the sub-cohort was 62.3 ± 6.9 
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years and 37% (n=603) were female. Of the 1614, 5.7% (n=92) died on study, 2.3% (n=37) due 
to cardiovascular disease. GGT had inverse associations with seven of the eight domains 
measured in the SF-36, while no significant associations were found for ALT (eTable 6). 
4. Discussion 
Similar to findings in the general population, there is an inverse association between ALT and 
mortality in those with type 2 diabetes and ALT less than two times the upper limit of normal. 
The paradoxical but more intuitive relationship between higher GGT and subsequent mortality 
was also seen in this subject group, although only at levels > 70 U/L. Of note, the HRs for ALT 
(per SD) and GGT (>70 U/L) as predictors of mortality, are similar to those of several established 
biomarkers, including hsCRP and homocysteine [27]. After adjustment, ALT was significantly 
associated with cardiovascular death only, whereas GGT was associated with death due to 
cardiovascular disease, cancer and non-cancer/non-cardiovascular causes (Table 3).  
To propose possible factors contributing to the association between lower ALT and mortality is 
challenging given that, similar to our findings (Table 2), increasing ALT has been directly linked 
to components of the metabolic syndrome and to markers of insulin resistance and systemic 
inflammation [1, 3, 6, 9]. The most widely accepted theory in current literature behind the 
association, is that low ALT is correlated with both frailty and sarcopenia, each associated with 
mortality in their own right [6, 7]. However, our analysis, while using surrogate techniques to 
adjust for frailty, did not support it as the principal mechanism involved. Indeed, if lower ALT 
was acting as a frailty marker alone to predict mortality, it would be expected to relate to all 
cause-specific categories of mortality (Table 3). In addition, we found exclusion of events at one 
and two years had no effect on the size of the risk. Similarly, no effect was seen after adjustment 
for proxy associations with frailty/co-morbidity including grade of current exercise capacity, 
employment status, eGFR, hsCRP, resting heart rate or weight loss within the first 12 months of 
the study (with greater weight loss presumed to be associated with frailty) [28] and associations 
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were strengthened when adjusted for sICAM, sVCAM and sE-Selectin. In addition, no clear 
relationship could be found between ALT and serum creatinine, an indirect marker of muscle 
mass (Table 2), or the individual scores for each domain of the SF-36 (eTable 6). These 
collective findings are not consistent with frailty as the primary contributor to the relationship 
seen [23, 25, 29]. 
Another possible cause of low ALT, and thus a potential contributor to its relationship with 
mortality, is a low liver reserve, as can be seen with aging [30-32] and cirrhosis, including that 
secondary to ‘burnt out’ NAFLD/NASH [13]. Indeed, the severity of fibrosis in NAFLD is 
thought to be the most important histological variable for predicting mortality [33, 34], including 
cardiovascular mortality [35]. It has also been linked to increased epicardial fat thickness, and 
abnormal cardiac geometry and function [36] and markers of subclinical atherosclerosis [37, 38]. 
Moreover, simple steatosis per se, may have no association with overall, or cardiovascular, 
mortality [35], particularly in the absence of other features of the metabolic syndrome [39]. Of 
note, adjusting for GGT, or excluding those with GGT > 70 U/L, increased rather than decreased 
the strength of the relationship between ALT and mortality. Of interest, the relationship was 
accentuated after adjustment for sICAM, sVCAM and sE-Selectin (eTable 4) and attenuated in 
those with an elevated hsCRP (Table 4), which would support the concept that a pro-
inflammatory state is not the primary driver of the inverse relationship seen. Those with high 
CRP are also more likely to have necroinflammation (NASH) [40], which may explain why those 
with higher ALT, presumed to represent NAFLD, and high CRP, are not relatively protected 
from death [41]. 
Alternative causes for the relationship between low ALT and mortality could include associations 
of low ALT with pyridoxine deficiency [9, 42], low levels of sex hormones [32, 43], higher N-
terminal pro-Brain natriuretic peptide (BNP, secreted by ventricular myocytes in response to 
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increased wall stress and ventricular filling pressure) [44] or genetic factors [1]. Given that higher 
ALT has been associated with markers of insulin resistance and higher BMI [45], low ALT may 
also be a sign of a more complex diabetes phenotype with greater absolute insulin deficiency, 
rather than insulin resistance, as a cause of hyperglycaemia [46, 47]. The stronger association of 
ALT with mortality in those with primary school education only is of interest (Table 4). This may 
reflect certain adverse environmental factors, to include diet and lifestyle, and unadjusted age 
related factors (with older subjects presumed to be less likely to have higher education) of 
importance but not defined in our data set [32].  
The finding of a positive association between GGT and mortality would be consistent with its 
known function as a sensitive but non-specific marker of liver injury, alcohol intake, oxidative 
stress, vascular disease and other co-morbidities, through primary pathology and also through 
enzyme induction from medications [1, 2, 4, 9-11, 48]. Indeed, this fact is supported by our 
finding that GGT >70 U/L associated with mortality in all three categories (cardiovascular, 
cancer and non-cardiovascular/non-cancer; Table 3). We found, as expected, clear associations 
between increasing GGT and several inflammatory markers and measures of insulin resistance 
and the relationship with GGT and mortality, while remaining significant, was weakened by 
adjustment for sVCAM, sICAM and sE-selectin (eTable 5). In addition, we found clear inverse 
associations between GGT and seven of the eight domains measured in the SF-36 (eTable 6), 
such that higher GGT was associated with lower physical and emotional function, again 
supporting an association of higher GGT with biological frailty. 
Surprisingly, the relationship between GGT and mortality was most clear in those without 
diagnosed hypertension and in those treated with diet alone (Table 4). These subgroups may 
include individuals who have less frequent medical contact or whose GGT elevation is due to 
causes other than medications, such as co-morbidity, alcohol intake or oxidative stress [1, 2, 9-
11]. The findings were stronger in those who consumed regular alcohol and were attenuated in 
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those who were abstinent, suggesting that excessive alcohol consumption is likely to play a 
significant role in this association [49]. 
Strengths of our analysis include the use of prospective data from a large, well-defined cohort, 
with pre-specified outcomes and novel vascular risk biomarkers. In addition, intra-individual 
variation in ALT was accommodated by using an average of two independent samples. The main 
weakness of the data set is the exclusion of subjects with ALT more than 2 times the upper limit 
of normal (>100 U/L), without clear restriction on GGT at study entry. Hence, we are unable to 
make any comment about higher levels of ALT, where, as in other publications, mortality may 
increase [50]. This exclusion may also at least partly explain the paradoxical associations 
between ALT and GGT and mortality observed. Despite this, our data set is consistent with 
multiple equivalent publications where higher ALT has been excluded in order to avoid the 
inclusion of individuals with significant liver disease [5, 51, 52]. Other weaknesses of our 
analysis include the lack of data for alcohol consumption in grams per week, although this is a 
notoriously difficult measure to quantify accurately [53], and also the possible inadequate period 
of follow-up to see the effects of an adverse metabolic profile that may be seen at higher levels of 
ALT. The markers of frailty were indirect and not tested with dual-energy X-ray absorptiometry 
(DEXA) or other standardised assessment tools. Exercise capacity was self-graded and did not 
include parameters for frequency and time and SF-36 data were only available in 16% of the 
cohort and therefore could not be used to adjust primary models. In addition, the FIELD cohort is 
generally considered to have a relatively ‘mild’ phenotype of type 2 diabetes, with relatively 
short diabetes duration, low complication rates and low rates of insulin use [54], although one 
could argue that it is reflective of a community-based cohort and thus more likely to have 
relevance to the general population than findings from individuals studied at a tertiary diabetes 
centre. Finally, while pre-specified, multiple interaction tests were applied to the data set to 
explore potential mechanisms behind the associations between ALT or GGT and mortality, 
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increasing the possibility of a chance finding. However, this analysis was subsidiary only and did 
not affect the main finding of our primary analysis. 
In summary, similar to findings in the general population, ALT has an inverse association with 
mortality in a community-based cohort of individuals with type 2 diabetes and ALT less than two 
times the upper limit of normal, despite the higher prevalence of NAFLD in this population [13]. 
This is opposite to the relationship seen for GGT and mortality, and both associations are of 
similar magnitude to those of biomarkers considered important predictors of mortality in 
populations with and without diabetes [27]. While GGT was associated with death due to 
cardiovascular disease, cancer and non-cancer/non-cardiovascular causes, low ALT was specific 
for death due to cardiovascular disease. The positive association between GGT and mortality 
would appear intuitive from our understanding of GGT as a marker of liver disease, alcohol 
intake, oxidative stress and co-morbidity [1, 2, 11]. The association between lower ALT, which is 
traditionally seen as a marker of liver health, and mortality is more difficult to understand [1, 45]. 
Mechanisms behind the inverse association between ALT and mortality have been reported by 
others to include frailty, sarcopenia and reduced liver reserve. However, links with frailty were 
neither supported nor conclusively refuted by our analysis and other factors are also likely to be 
important in those with type 2 diabetes [5, 7, 23]. Research into the causes, liver-related or 
otherwise, behind the association between low ALT and mortality is needed. 
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9. Tables 
Table 1: Clinical and biochemical characteristics of those who survived compared with 
those who died on the study.  
Baseline variable Survivors Died on study p value 
Fenofibrate use 4539 (50%) 356 (52%) 0.19 
Age (years) 62 (56–67) 67 (62–71) <0.001 
Female 3473 (38%) 184 (27%) <0.001 
Residence in Australia or New 
Zealand 7805 (86%) 597 (88%) 0.10 
Diabetes duration (years) 5 (2–10) 7 (3–12) <0.001 
Current smoker 812 (9%) 110 (16%) <0.001 
Hypertension 5113 (56%) 433 (64%) <0.001 
Nephropathy 2228 (24%) 280 (41%) <0.001 
Prior cardiovascular disease 1865 (20%) 275 (41%) <0.001 
Diabetes treatment    
 Diet 2483 (27%) 125 (19%) <0.001 
 Oral 5425 (60%) 416 (61%)  
 Insulin ± oral 1208 (13%) 138 (20%)  
HbA1c (%) 6.9 (6.1–7.8) 7.2 (6.3–8.2) <0.001 
HbA1c (mmol/mol) 52 (43–62) 55 (45–66)  
ALT (U/L) 24 (18–33) 22 (17–29) <0.001 
GGT (U/L) 29 (21–44) 31 (22–50) <0.001 
Data are presented as number (%) or median and interquartile range.  
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Table 2A and 2B: Clinical and biochemical associations with baseline alanine 
aminotransferase (ALT) and γ-glutamyl transferase (GGT) levels 
 Table 2A. Clinical associations with baseline ALT and GGT 
 ALT GGT 
Baseline clinical characteristic 
Median and 
IQR (U/L) or 
correlation 
coefficient p value 
Median and 
IQR (U/L) or 
correlation 
coefficient p value 
Age (years) –0.21 <0.001 –0.13 <0.001 
Sex  <0.001  <0.001 
 Female (n=3657, 37%) 21 (16–29)  26 (19–40)  
 Male 25 (19–35)  31 (22–46)  
Country of recruitment  <0.001  <0.001 
 Australia and New Zealand (n=8402, 86%) 23 (18–32)  29 (21–43)  
 Finland 26 (19–37)  32 (22–48)  
Waist-hip ratio 0.26 <0.001 0.25 <0.001 
Body mass index (kg/m2) 0.19 <0.001 0.21 <0.001 
Diabetes duration (years) –0.041 <0.001 –0.05 <0.001 
Smoking status  <0.001  <0.001 
 Non-smoker (n=3929, 40%) 23 (17–32)  27 (19–40)  
 Ex-smoker (n=4944, 51%) 25 (19–34)  30 (22–46)  
 Current smoker (n=922, 9%) 23 (17–31)  31 (22–47)  
Alcohol intake  <0.001  <0.001 
 None (n=2691, 28%) 23 (17–31)  27 (20–40)  
 Infrequent (n=4604, 47%) 24 (18–32)  28 (20–42)  
 Regular (n=2494, 25%) 25 (19–35)  34 (24–52)  
Comorbidity     
 Hypertension (n=5546, 57%) 24 (18–33)  0.34 30 (22–46) <0.001 
 No hypertension 24 (18–32)  28 (20–41)  
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 ALT GGT 
Baseline clinical characteristic 
Median and 
IQR (U/L) or 
correlation 
coefficient p value 
Median and 
IQR (U/L) or 
correlation 
coefficient p value 
   Systolic blood pressure (mmHg) 0.03 0.02 0.07 <0.001 
   Diastolic blood pressure (mmHg) 0.15 <0.001 0.13 <0.001 
 Dyslipidaemia (n=3710, 38%) 25 (19–35) <0.001 31 (23–46) <0.001 
 No dyslipidaemia 23 (17–31)  28 (20–42)  
   Known cardiovascular disease (n=2131, 
22%) 23 (18–31) 
<0.001 29 (21–45) 0.08 
 No known cardiovascular disease 24 (18–33)  29 (21–44)  
 Nephropathy (n=2508, 26%) 24 (18–34) 0.007 32 (23–48) <0.001 
 No nephropathy 24 (18–32)  28 (20–42)  
Diabetes treatment  <0.001  <0.001 
 Diet only (n=2608, 26%) 23 (18–31)  28 (20–40)  
 Oral antidiabetic therapy (n=5841, 60%) 25 (18.0–34)  30 (22–46)  
 Insulin ± oral antidiabetic therapy (n=1346, 
14%) 23 (17.0–30)
 28 (19–43)  
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Table 2B: Association of laboratory measures with baseline alanine aminotransferase 
(ALT) and γ-glutamyl transferase (GGT) 
 ALT GGT 
Laboratory measure 
Median and 
IQR (U/L) or 
correlation 
coefficient p value 
Median and 
IQR (U/L) or 
correlation 
coefficient p value 
 HbA1c (% or mmol/mol) 0.12 <0.001 0.12 <0.001 
 Fasting glucose (mmol/L) 0.16 <0.001 0.14 <0.001 
 C-peptide (nmol/L) 0.29 <0.001 0.30 <0.001 
 HDL-c (mmol/L) –0.15 <0.001 –0.09 <0.001 
 LDL-c (mmol/L) –0.09 <0.001 –0.09 <0.001 
 Triglyceride (mmol/L) 0.15 <0.001 0.21 <0.001 
 Lipoprotein a (µmol/L) –0.10 <0.001 –0.10 <0.001 
 hsCRP (mg/L) –0.01 0.49 0.18 <0.001 
 Uric acid (μmol/L) 0.11 <0.001 0.14 <0.001 
 Serum Creatinine (μmol/L) 0.06 <0.001 0.03 0.002 
 eGFR (MDRD, 
ml/min/1.73m2) 0.09 
<0.001 0.08 <0.001 
 Platelets (x109/L) –0.14 <0.001 –0.09 <0.001 
 HOMA IR 0.32 <0.001 0.33 <0.001 
 Homocysteine (µmol/L) –0.06 <0.001 0.01 0.30 
 sVCAM (U/L) 0.11 <0.001 0.12 <0.001 
 sICAM (U/L) 0.19 <0.001 0.26 <0.001 
 sE-selectin (U/L) 0.36 <0.001 0.33 <0.001 
 Fibrinogen (µmol/L) –0.02 0.13 0 0.81 
 ALT (U/L) –  0.51 <0.001 
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Table 3: Relationship between baseline alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT) > 70 U/L and all-cause and 
cause-specific mortality on study.  
Cause of death 
ALT per 13.2U/L GGT > 70 U/L vs. GGT ≤ 70 U/L 
Univariable Multivariablea Univariable Multivariablea 
HR 
(95%CI) 
p 
value 
HR 
(95%CI) 
p 
value 
HR 
(95%CI) 
p 
value HR (95%CI) 
p 
value 
All-cause (n=679) 0.81 (0.74–0.88) <0.001 0.85 (0.78–0.93) <0.001 1.88 (1.53–2.30) <0.001 1.82 (1.48–2.24) <0.001 
Cancer (n=267) 0.88 (0.77–1.00) 0.47 0.93 (0.81–1.07) 0.32 1.82 (1.35–2.44) 0.001 1.81 (1.33–2.47) <0.001 
Cardiovascular (n=316) 0.74 (0.64–0.86) 0.001 0.77 (0.67–0.90) 0.001 1.63 (1.16–2.28) 0.005 1.46 (1.03–2.07) 0.03 
Non-cancer, non-
cardiovascular (n=96) 
0.78 (0.63–0.97) 0.03 0.85 (0.69–1.05) 0.14 2.58 (1.59–4.19) <0.001 2.59 (1.57–4.26) <0.001 
 
 
a The multivariable model was adjusted for the pre-specified variables of assignment to fenofibrate, age, sex, diabetes duration, current smoker status, 
hypertension, dyslipidaemia, nephropathy, prior cardiovascular disease, waist-hip ratio, LDL-c and HbA1c.
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Table 4: Relationship between baseline alanine aminotransferase (ALT) and γ-glutamyl 
transferase (GGT) >70 U/L and all-cause mortality using subgroup analysis, as defined by 
variables with a statistically significant interaction with ALT or GGT > 70 U/L.  
Variable (deaths/total number of individuals in analysis) HR (95% CI) p value 
Interaction
p value 
ALT per SD (13.2 U/L)    
 Subpopulation with hsCRP ≤ 6.0 mg/L (466/7275) 0.81 (0.72–0.90) <0.001 0.03 
 Subpopulation with hsCRP > 6.0 mg/L (206/2321) 0.98 (0.85–1.14) 0.82  
 Subpopulation with primary school education only (138/1484) 0.67 (0.54–0.85) 0.001 0.03 
 Subpopulation with high school education or higher (538/8254) 0.89 (0.81–0.99) 0.03  
GGT > 70 U/L    
 Subpopulation with hypertension (432/5527) 1.41 (1.07–1.85) 0.01 0.001 
 Subpopulation with no hypertension (246/4238) 2.74 (2.00–3.75) <0.001  
 Subpopulation on diet control for diabetes (124/2588) 3.06 (1.94–4.81) <0.001 0.03 
 Subpopulation on oral antidiabetic therapy (416/5833) 1.69 (1.29–2.20) <0.001  
 Subpopulation on insulin ± oral antidiabetic therapy (138/1344) 1.48 (0.92–2.38) 0.11  
 Subpopulation with hsCRP ≤ 6.0 mg/L (466/7275) 1.53 (1.16–2.02) 0.003 0.001 
 Subpopulation with hsCRP > 6.0 mg/L (206/2321) 2.22 (1.61–3.07) <0.001  
 Subpopulation who consume no alcohol (215/2685) 1.17 (0.74–1.85) 0.50 0.007 
 Subpopulation who consume infrequent alcohol (303/4591) 1.83 (1.33–2.53) <0.001  
 Subpopulation who consume regular alcohol (160/2483) 2.53 (1.78–3.60) <0.001  
 a All models were adjusted for the pre-specified variables of assignment to fenofibrate, age, sex, diabetes 
duration, current smoker status, hypertension, dyslipidaemia, nephropathy, prior cardiovascular disease, 
waist-hip ratio, LDL-c and HbA1c. 
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10. Figure legends 
Figure 1 
Graphical depiction of unadjusted natural log of hazard ratios (HR) and 95% confidence intervals 
for all-cause mortality on study for alanine aminotransferase (ALT) deciles (Panel 1A) and γ-
glutamyl transferase (GGT) deciles (Panel 1C) and their associated Kaplan Meier graphs (Panels 
1B and 1D) using Cox proportional hazards regression analysis. 
Figure 2 
Graphical depiction of unadjusted hazard ratios (HR) and 95% confidence intervals for death on 
study by cause-specific mortality subtype using competing risk analysis (Fine and Gray) for 
alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT) deciles. Abbrev: CVD, 
cardiovascular. 
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